Navigation Links
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
Date:9/17/2013

and strategic partnership activities in key international markets.  In terms of the U.S. market, we already began enrollment for our FDA-intended MASTER II trial.  And as we expand our current clinical activities for the Coronary market, we continue to bolster our product pipeline with advances for the Carotid and Peripheral Vasculature target indications," concluded Mr. Milinazzo.

Operational Overview  In fiscal year 2013, the Company announced superior results from the MASTER trial for its MGuard Embolic Protection Stent (EPS).The findings show the novel MGuard EPS provides a significant acute advantage in reducing ST segment elevation versus traditional bare metal and drug eluting stents. As a result, MGuard may hold the potential to prolong the survival of heart attack victims, as evidenced by the 30-day and 6-month data. 

The MASTER trial is an important study for InspireMD, as it is the first large, randomized clinical trial for the MGuard to date. As such, the results have gained much more credence among those in the medical community. The 12-month follow up results for the MASTER trial, scheduled to be released on October 29th, are expected to be an important data point for physicians evaluating the MGuard, as the first year is an important period for evaluating a patient that has received a stent during a heart attack. 

The results disclosed thus far from the MASTER trial have allowed the Company to begin the transition to a new commercial strategy in countries where the MGuard has received regulatory clearance.  This includes setting up the support structure for a direct sales team in certain European countries and advancing discussions with new strategic partners.  The Company recently entered into an agreement with Healthlink Europe, a medical device support services and distribution company, to provide logistical and customer support for InspireMD's commercial operations and clinical
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 XBiotech announced ... study in patients with moderate to severe plaque ... open-label Phase II trial evaluated the potential benefit ... that targets interleukin-1 alpha (IL-1a). IL-1a is a ... present in skin lesions. The Company claims that ...
(Date:3/4/2015)... , March 4, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization of ... it will present at the Barclays Global Healthcare ... the Loews Miami Beach Hotel in Miami ... Peter , M.D., President and Chief Executive Officer of ...
(Date:3/4/2015)... -- Following the reintroduction of the Comprehensive Addiction ... a report today urging policymakers to take steps ... through more effective use of medication-assisted treatment (MAT).  ... Expanding Access to Medication-Assisted Treatment to Address the ... and economic advantages of medication-assisted treatment along with ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2
... According to an overview of industry data released ... , in Fiscal Year 2011, pharmaceutical companies continued a ... delay the introduction of lower-cost prescription drug alternatives for ... that drug companies entered into 28 potential pay-for-delay ...
... ABAXIS, Inc. (NasdaqGS: ABAX), a medical products company manufacturing ... the second fiscal quarter ended September 30, 2011. ... $40.0 million, up 13% over last year,s comparable quarter. ... over last year,s comparable quarter. Veterinary market sales ...
Cached Medicine Technology:FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 2FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 2Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 4Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 5Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 6Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 7Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 8Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 9
(Date:3/4/2015)... Imagine No Malaria’s 2014 World Malaria Day campaign has ... an honor given to nonprofit causes that make a difference. ... Conference (NTC15) in Austin, Texas. The Rev. Bobbi Kaye ... was on hand for the presentation; she is a member ... No Malaria was one of five finalists selected by Care2, ...
(Date:3/4/2015)... 04, 2015 Dr. Christopher Asandra, M.D., ... Center today lamented the FDA’s recent decision to ... (TRT). He argued that FDA’s conclusions are not supported ... who suffer from testosterone deficiency. , “The FDA appears ... testosterone replacement therapy,” said Dr. Asandra. “There is not ...
(Date:3/4/2015)... Austria (PRWEB) March 04, 2015 ... reduce subjectivity in density assessment and help improve ... of numerous abstracts accepted for presentation at the ... 2015. Ten abstracts - eight posters and ... Volpara Solutions’ automated breast density and quantitative breast ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Starting February ... LASIK and PRK procedures at their new location in ... Dr. Joseph King and Dr. Gabriel Chu also provide ... in Surrey is named Fraser Valley Cataract and Laser ... accredited by the College of Physicians and Surgeons of ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 State officials ... of the School of Public Health at Georgia State ... funds were awarded by Georgia’s Division of Family and ... support the DFCS Call Center. , The 1-800-CHILDREN ... by providing information and referral services that promote the ...
Breaking Medicine News(10 mins):Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:King LASIK relocates to Surrey, British Columbia 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2
... CHICAGO For years, it was believed that obese women ... body fat actually protected against bone loss. However, a study ... of North America (RSNA) found that having too much internal ... bone health. "We know that obesity is a major ...
... , CAMBRIDGE, Mass. (November 29, 2010) Whitehead Institute ... the microRNA 125b (miR-125b) can independently cause leukemia and ... this week,s online edition of the Proceedings of the ... in many cancers, but in humans and mice, can ...
... With the emergence of an epidemic of obesity and type ... habits that may affect the risk of metabolic diseases is ... drinkers tend to have about 30% lower risk of developing ... tend to be at lower risk of developing metabolic ...
... Goodwin HealthDay Reporter , MONDAY, Nov. 29 (HealthDay ... teens over the last few decades, with some of the ... a new report. In one startling statistic cited in ... and Quality found that hospitalizations for eating disorders jumped by ...
... iridescence of a butterfly,s wing, investigators at the University ... and Applied Sciences have developed a color-changing patch that ... indicate the strength of exposure to blasts from explosives ... color change to the intensity of exposure to provide ...
... , MONDAY, Nov. 29 (HealthDay News) -- Children and teens ... triclosan may be at increased risk for hay fever and ... can actually make people sick, researchers say. The study ... bisphenol A (BPA) may weaken an adult,s immune system. ...
Cached Medicine News:Health News:Belly fat puts women at risk for osteoporosis 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:Moderate alcohol consumption lowers the risk of metabolic diseases 2Health News:Rate of Eating Disorders in Kids Keeps Rising 2Health News:Rate of Eating Disorders in Kids Keeps Rising 3Health News:Color-changing 'blast badge' detects exposure to explosive shock waves 2Health News:Too Much Hygiene May Affect Immune System, Study Suggests 2
This optimal design addresses low-cost, simple, non-invasive ankle distraction....
A straightforward, versatile approach to arthroscopically assisted pin placement in either the ankle or wrist....
... The BTA stat Test ... for the qualitative detection of ... persons diagnosed with bladder cancer. ... as an aid in the management ...
ThyroTest by ThyroTec, Inc. is a rapid immunoassay, similar to a rapid pregnancy test. By using 2 drops of blood from a finger stick and 5 drops of diluent, a qualitative TSH level is inicated in min...
Medicine Products: